Luseogliflozin Suppresses Fine Glycemic Fluctuation Late at Night: New Aspect of SGLT2 Inhibitor

被引：0
|
作者：
Yamauchi, Keishi
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-798-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
798-P
引用
收藏
页数：3
相关论文
共 50 条
  • [21] SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes
    Takiyama, Yumi
    Bessho, Ryoichi
    Maeda, Manami
    Atageldiyeva, Kuralay K.
    Yanagimachi, Tsuyoshi
    Honjo, Jun
    Fujita, Yukihiro
    Makino, Yuichi
    Haneda, Masakazu
    DIABETES, 2014, 63 : A136 - A136
  • [22] Effects of SGLT2 inhibitor luseogliflozin under different dietary formula in type 2 diabetes: A randomized, controlled exploratory trial
    Kuwata, Hitoshi
    Iwasaki, Masahiro
    Kanada, Shigeto
    Yabe, Daisuke
    Seino, Yutaka
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S52 - S52
  • [23] Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
    Samukawa, Yoshishige
    Haneda, Masakazu
    Seino, Yutaka
    Sasaki, Takashi
    Fukatsu, Atsushi
    Kubo, Yusuke
    Sato, Yuri
    Sakai, Soichi
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (08): : 820 - 828
  • [24] Protective Effects of SGLT2 Inhibitor Luseogliflozin on Pancreatic Beta Cells in Obese Type 2 Diabetic db/db Mice
    Okauchi, Seizou
    Simoda, Masashi
    Obata, Atsushi
    Kimura, Tomohiko
    Hirukawa, Hidenori
    Kohara, Kenji
    Kaneto, Hideaki
    Kaku, Kohei
    DIABETES, 2015, 64 : A586 - A586
  • [25] Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice
    Bamba, Ryo
    Okamura, Takuro
    Hashimoto, Yoshitaka
    Majima, Saori
    Senmaru, Takafumi
    Ushigome, Emi
    Nakanishi, Naoko
    Asano, Mai
    Yamazaki, Masahiro
    Takakuwa, Hiroshi
    Hamaguchi, Masahide
    Fukui, Michiaki
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2022, 13 (01) : 574 - 588
  • [26] The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy
    Ali, Amr
    Mekhaeil, Bassem
    Biziotis, Olga-Demetra
    Tsakiridis, Evangelia E.
    Ahmadi, Elham
    Wu, Jianhan
    Wang, Simon
    Singh, Kanwaldeep
    Menjolian, Gabe
    Farrell, Thomas
    Mesci, Aruz
    Liu, Stanley
    Berg, Tobias
    Bramson, Jonathan L.
    Steinberg, Gregory R.
    Tsakiridis, Theodoros
    COMMUNICATIONS BIOLOGY, 2023, 6 (01)
  • [27] The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy
    Amr Ali
    Bassem Mekhaeil
    Olga-Demetra Biziotis
    Evangelia E. Tsakiridis
    Elham Ahmadi
    Jianhan Wu
    Simon Wang
    Kanwaldeep Singh
    Gabe Menjolian
    Thomas Farrell
    Aruz Mesci
    Stanley Liu
    Tobias Berg
    Jonathan L. Bramson
    Gregory R. Steinberg
    Theodoros Tsakiridis
    Communications Biology, 6
  • [28] In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor
    Chino, Yukihiro
    Hasegawa, Masatoshi
    Fukasawa, Yoshiki
    Mano, Yoko
    Bando, Kagumi
    Miyata, Atsunori
    Nakai, Yasuhiro
    Endo, Hiromi
    Yamaguchi, Jun-ichi
    XENOBIOTICA, 2017, 47 (04) : 314 - 323
  • [29] Luseogliflozin (TS-071), a novel SGLT2 inhibitor, protects against diabetic nephropathy in diabetic db/db mice
    Takiyama, Y.
    Agatsuma, K.
    Yasuda-Kobayashi, M.
    Honjo, J.
    Fujita, Y.
    Yanagimachi, T.
    Kitsunai, H.
    Makino, Y.
    Haneda, M.
    DIABETOLOGIA, 2013, 56 : S66 - S66
  • [30] Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats
    Rahman, Asadur
    Fujisawa, Yoshihide
    Nakano, Daisuke
    Hitomi, Hirofumi
    Nishiyama, Akira
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2017, 44 (04) : 522 - 525
12345